These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 9024235)

  • 1. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
    Rappaport R; Mugnier E; Limoni C; Crosnier H; Czernichow P; Leger J; Limal JM; Rochiccioli P; Soskin S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.
    Pasquino AM; Pucarelli I; Roggini M; Segni M
    J Clin Endocrinol Metab; 2000 Feb; 85(2):619-22. PubMed ID: 10690865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years.
    de Zegher F; Albertsson-Wikland K; Wollmann HA; Chatelain P; Chaussain JL; Löfström A; Jonsson B; Rosenfeld RG
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2816-21. PubMed ID: 10946888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone (GH)-binding protein in prepubertal short children born small for gestational age: effects of growth hormone treatment. Swedish Study Group for Growth Hormone Treatment.
    Boguszewski M; Bjarnason R; Rosberg S; Carlsson LM; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1014-9. PubMed ID: 9100566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age.
    van Pareren YK; Duivenvoorden HJ; Slijper FS; Koot HM; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5295-302. PubMed ID: 15531473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A; Simon D; Czernichow P
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial.
    Mericq MV; Eggers M; Avila A; Cutler GB; Cassorla F
    J Clin Endocrinol Metab; 2000 Feb; 85(2):569-73. PubMed ID: 10690857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial.
    Van Pareren Y; Mulder P; Houdijk M; Jansen M; Reeser M; Hokken-Koelega A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3584-90. PubMed ID: 12915640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
    Zenaty D; Garel C; Limoni C; Czernichow P; Léger J
    Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Jansen M; Otten BJ; Delemarre-van de Waal HA; Vulsma T; Wit JM; Rouwé CW; Reeser HM; Gosen JJ; Rongen-Westerlaken C; Drop SL
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of growth deceleration after withdrawal of growth hormone therapy in idiopathic short stature.
    Lampit M; Hochberg Z
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3573-7. PubMed ID: 12161476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens.
    van Pareren YK; de Muinck Keizer-Schrama SM; Stijnen T; Sas TC; Jansen M; Otten BJ; Hoorweg-Nijman JJ; Vulsma T; Stokvis-Brantsma WH; Rouwé CW; Reeser HM; Gerver WJ; Gosen JJ; Rongen-Westerlaken C; Drop SL
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1119-25. PubMed ID: 12629094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study.
    Saggese G; Federico G; Barsanti S; Fiore L
    J Clin Endocrinol Metab; 2001 May; 86(5):1900-4. PubMed ID: 11344181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
    Ross JL; Lee PA; Gut R; Germak J
    Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database).
    Geffner M; Lundberg M; Koltowska-Häggström M; Abs R; Verhelst J; Erfurth EM; Kendall-Taylor P; Price DA; Jonsson P; Bakker B
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5435-40. PubMed ID: 15531494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.